Cargando…
Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
Autores principales: | Slootbeek, Peter H. J., Kloots, Iris S. H., Smits, Minke, van Oort, Inge M., Gerritsen, Winald R., Schalken, Jack A., Ligtenberg, Marjolijn J. L., Grünberg, Katrien, Kroeze, Leonie I., Bloemendal, Haiko J., Mehra, Niven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980086/ https://www.ncbi.nlm.nih.gov/pubmed/35210590 http://dx.doi.org/10.1038/s41416-022-01765-y |
Ejemplares similares
-
Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2021) -
Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2023) -
Impact of DNA damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2020) -
Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer
por: Smits, Minke, et al.
Publicado: (2020) -
Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
por: van Wilpe, Sandra, et al.
Publicado: (2021)